Detection and comparison of a 90-kd glycoprotein tumor-associated antigen-specific immune-complexes with cea and ca15-3 in breast-cancer.
Serum samples selected randomly from 106 patients that had histopathologically proven breast cancer, and from 107 self-proclaimed and apparently healthy females were analyzed for the presence of a 90 kD subunit containing glycoprotein TAA-specific immune complexes (IC) by a murine monoclonal antibody based ELISA. The incidence of the glycoprotein antigen specific IC in breast cancer patients was 63% (67/106), as indicated by the normalized ELISA value above 0.410 OD405nm. On the contrary, only 3 (2.8%) of 107 apparently healthy controls had positive ELISA value (p<0.05). Comparison of the glycoprotein TAA-specific IC results in breast cancer patients with evidence of disease with the results of CEA and CA15-3 revealed that the incidence of abnormal values was increased to 91%. Thus, use of the glycoprotein TAA specific-IC marker in conjunction with CEA and/or CA15-3 may prove to be more sensitive than when used alone for immunodiagnosis and immunoprognosis.